Denise Devore

Denise Devore

Auto-generated profile, based on publicly available information

Denise Devore

Pharmacology, Alexion, AstraZeneca Rare Disease Boston Massachusetts USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2024 in mAbs
Verified
Journal Article
Open access
PTPaul Tamburini
Paul Tamburini
DPDennis Vestergaard Pedersen
Dennis Vestergaard Pedersen
DDDenise Devore
Denise Devore
JCJosh Cone
Josh Cone
RPRekha Patel
Rekha Patel
JHJeffrey Hunter
Jeffrey Hunter
The bispecific antibody tarperprumig (ALXN1820) was developed as a treatment option for diseases involving dysregulated complement alternative pathway (AP) activity that could be administered in small volumes, either subcutaneously or intravenously. Tarperprumig incorporates a C-terminal variable domain of a heavy chain only antibody (VHH) that binds properdin (FP) connected via a flexible linker to an N-terminal VHH that binds human serum albumin (HSA). The purified bispecific VHH antibody exhibits an experimental molecular weight average of 27.4 kDa and can be formulated at > 100 mg/mL. Tarperprumig binds tightly to FP and HSA with sub-nanomolar affinity at pH 7.4 and can associate simultaneously with FP and HSA to form a ternary complex. Tarperprumig potently and dose-dependently inhibits to completion in vitro AP-dependent complement C5b-9 formation, AP-dependent hemolysis, and the AP deposition of C3, FP and C9. X-ray crystallography revealed that the isolated FP-binding VHH recognizes the thrombospondin repeat 5 domain of FP, thereby preventing FP from binding to the AP convertase owing to severe steric hindrance. Tarperprumig cross-reacts with cynomolgus monkey FP and serum albumin. In summary, tarperprumig exhibits properties tailored for subcutaneous administration and is currently in clinical development for the treatment of complement AP-related disorders.

31 December 2025 in JIMD Reports
Verified
Journal Article
Open access
DDDenise Devore
Denise Devore
JRJuan Ruanova
Juan Ruanova
WVWalter Voegtli
Walter Voegtli
DDDerek Dunn
Derek Dunn
JDJohn Decker
John Decker
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
Hypophosphatasia (HPP) is an inherited metabolic disease caused by deficient tissue‐nonspecific alkaline phosphatase (ALP) activity and characterized by skeletal and nonskeletal symptoms, including muscle weakness and fatigue. We hypothesized that mitochondrial respiration is impaired in muscle in HPP, independent of skeletal manifestations, and that the second‐generation ALP enzyme replacement therapy (ERT) efzimfotase alfa improves respiration. Akp2GW −/− mice were used for this purpose. Body weight, bone mineralization, and survival were validated in Akp2GW −/− mice versus Akp2 −/− mice, an established model of HPP. No significant differences were found, validating the Akp2GW −/− model. Respiratory outcomes were measured in skeletal muscle fiber bundles in age‐ and sex‐matched Akp2GW −/− and Akp2GW +/+ (wild‐type) mice; bone mineralization was assessed. Mean maximal respiration and mitochondrial spare respiratory capacity (SRC) in vehicle‐treated Akp2GW −/− mice were 37% and 30% of values from wild‐type mice, respectively, independent of skeletal manifestations. Efzimfotase alfa treatment significantly improved maximal respiration in tissue from Akp2GW −/− mice by 147% versus vehicle ( p = 0.0059) and improved SRC by 262% versus vehicle ( p = 0.0008). Mean maximal respiration and SRC in tissue from efzimfotase alfa‐treated Akp2GW −/− mice were 92% and 107%, respectively, of tissue from wild‐type mice. Cellular ultrastructure of muscle biopsies from people with HPP showed atypical mitochondrial morphology, including branching cristae and dispersed matrix. In a mouse model of HPP, we show that the altered mitochondrial respiration in skeletal muscle is improved by ERT and that HPP is characterized by altered muscle mitochondrial morphology in humans. Together, these data suggest ERT could improve muscular symptoms in HPP.